Hudson Bay Capital Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Hudson Bay Capital Management’s Portfolio EUCR Stock Details EUCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-650,920	Closed	-$6.53M	–	1221
2022 Q3	$6.53M	Sell	650,920 -36,608	-5%	-$365K	0.06%	297
2022 Q2	$6.81M	Buy	687,528 +175,000	+34%	+$1.73M	0.05%	304
2022 Q1	$5.05M	Buy	512,528 +79,146	+18%	+$777K	0.07%	355
2021 Q4	$4.23M	Hold	433,382	–	–	0.04%	402
2021 Q3	$4.24M	Hold	433,382	–	–	0.06%	409
2021 Q2	$4.27M	Buy	433,382 +36,902	+9%	+$363K	0.05%	401
2021 Q1	$3.92M	Sell	396,480 -3,519	-0.9%	-$36.1K	0.05%	370
2020 Q4	$4.02M	Buy	+399,999	New	+$4.03M	0.04%	267

Other funds holding EUCR

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Hudson Bay Capital Management's EUCR Position: Q4 2022 in Review

Hudson Bay Capital Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q4 2022, closing a stake of 650,920 shares — an estimated $6.53M sold.

Hudson Bay Capital Management first reported a position in EUCR in Q4 2020 and held it in 8 quarters. The position peaked at $6.81M in Q2 2022. 5 funds tracked by Wall St. Rank hold EUCR as of Q4 2022.

Hudson Bay Capital Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Hudson Bay Capital Management sold 650,920 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q4 2022, an estimated $6.53M.
Hudson Bay Capital Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2020 and held it in 8 quarters.
Hudson Bay Capital Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $6.81M in Q2 2022.
5 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q4 2022.

Based on Hudson Bay Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.